Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Assets Average (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Assets Average for 5 consecutive years, with $245.5 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 31.72% to $245.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $245.5 million through Dec 2025, down 31.72% year-over-year, with the annual reading at $300.0 million for FY2025, 6.74% down from the prior year.
  • Assets Average for Q4 2025 was $245.5 million at TScan Therapeutics, down from $280.4 million in the prior quarter.
  • The five-year high for Assets Average was $361.4 million in Q3 2024, with the low at $158.9 million in Q3 2022.
  • Average Assets Average over 5 years is $252.2 million, with a median of $251.0 million recorded in 2024.
  • The sharpest move saw Assets Average surged 91.37% in 2023, then tumbled 31.72% in 2025.
  • Over 5 years, Assets Average stood at $196.5 million in 2021, then dropped by 7.24% to $182.3 million in 2022, then surged by 54.58% to $281.8 million in 2023, then increased by 27.61% to $359.6 million in 2024, then crashed by 31.72% to $245.5 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $245.5 million, $280.4 million, and $315.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.